Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2011
This article has no abstract
Epistemonikos ID: d38ba9cb8246c6a8428c2e5e71bc9b34c403fa8e
First added on: Feb 04, 2025